Is Vilin Bio Med overvalued or undervalued?

As of 18 September 2025, the valuation grade for Vilin Bio Med has moved from expensive to very expensive. This indicates a significant increase in perceived valuation, suggesting that the company is currently overvalued. The key ratios reveal a PE ratio of 34.94, an EV to EBITDA of 37.46, and a ROCE of just 2.66%, which are notably high compared to industry standards.
In comparison to peers, Vilin Bio Med's PE ratio is higher than Sun Pharma's at 34.46 and significantly above Cipla's attractive valuation with a PE of 23.65. Additionally, the company's PEG ratio of 0.93 suggests that while growth expectations may be favorable, the current price does not justify the valuation when compared to its peers. Recent stock performance shows a 1-year return of 38.78%, which outpaces the Sensex's 0.18%, yet this does not mitigate the overvaluation indicated by the current metrics.